ERBB2 and breast cancer: Our recent study found that KIR2DL4 synergizes with FcRγ to enhance NK cell activation and degranulation, while HLA-G binding to KIR2DL4 impairs the cytotoxicity of NK cells in HER2 positive breast cancer microenvironment (7).